efavirenz has been researched along with Fatty Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X; Guo, X; Miao, X; Su, F; Ye, H | 1 |
| Greenberg, RN; Gwag, T; Helsley, RN; Meng, Z; Park, SH; Sui, Y; Wang, S; Zhou, C | 1 |
2 other study(ies) available for efavirenz and Fatty Liver
| Article | Year |
|---|---|
Resveratrol attenuates efavirenz-induced hepatic steatosis and hypercholesterolemia in mice by inhibiting pregnane X receptor activation and decreasing inflammation.
Topics: Animals; Cholesterol; Fatty Liver; Hypercholesterolemia; Inflammation; Male; Mice; Pregnane X Receptor; Resveratrol | 2023 |
Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis.
Topics: Alkynes; Animals; Benzoxazines; CD36 Antigens; Cholesterol; Cyclopropanes; Fatty Liver; Hepatocytes; Humans; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Pregnane X Receptor; Reverse Transcriptase Inhibitors; Signal Transduction; Squalene Monooxygenase | 2019 |